Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fresenius SE KGaAXSWX:FRE 67 3-Year FCF Growth Rate is -29.10% as of Mar. 2026. GuruFocus rates XSWX:FRE with a GF Score™ of 67/100 and a GF Value™ of CHF33.48 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 467 Healthcare Providers & Services companies, Fresenius SE KGaA ranks worse than 86.72% on this metric.
During the past 12 months, Fresenius SE KGaA's average Free Cash Flow per Share Growth Rate was -0.60% per year.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was -29.10% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was -18.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Fresenius SE KGaA was 57.20% per year. The lowest was -61.20% per year. And the median was -12.20% per year.
Fresenius SE KGaA (XSWX:FRE) 3-Year FCF Growth Rate Explanation
Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.
Fresenius SE KGaA 3-Year FCF Growth Rate Related Terms
XSWX:FRE vs HCA, THC, DVA: 3-Year FCF Growth Rate Comparison
For the Medical Care Facilities subindustry, Fresenius SE KGaA's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fresenius SE KGaA 3-Year FCF Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Fresenius SE KGaA's 3-Year FCF Growth Rate distribution charts can be found below:
* The bar in red indicates where Fresenius SE KGaA's 3-Year FCF Growth Rate falls into.
Fresenius SE KGaA 3-Year FCF Growth Rate Calculation
This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
What does a 3-Year FCF Growth Rate of -29.10% mean?
Fresenius SE KGaA (XSWX:FRE) has a 3-Year FCF Growth Rate of -29.10% as of Mar. 2026. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Fresenius SE KGaA and its competitors. According to the industry distribution chart, Fresenius SE KGaA ranks #405 out of 467 companies in the Healthcare Providers & Services industry, placing it in the top 86.7%.
Is Fresenius SE KGaA's 3-Year FCF Growth Rate too high?
Fresenius SE KGaA's current 3-Year FCF Growth Rate is -29.10%. Based on the distribution chart, Fresenius SE KGaA ranks #405 out of 467 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Fresenius SE KGaA has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fresenius SE KGaA's 3-Year FCF Growth Rate compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Fresenius SE KGaA ranks #405 out of 467 companies for 3-Year FCF Growth Rate. This places Fresenius SE KGaA in the lower half of its industry. The industry median 3-Year FCF Growth Rate is 13.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year FCF Growth Rate for a Healthcare Providers & Services company?
The median 3-Year FCF Growth Rate among Healthcare Providers & Services companies is 13.40, based on 467 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year FCF Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year FCF Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year FCF Growth Rate mean?
A high 3-Year FCF Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Fresenius SE KGaA and its competitors. For the Healthcare Providers & Services industry, the median 3-Year FCF Growth Rate is 13.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fresenius SE KGaA's current 3-Year FCF Growth Rate is -29.10%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fresenius SE KGaA stock overvalued right now?
Based on GuruFocus' analysis, Fresenius SE KGaA (XSWX:FRE) is currently considered Modestly Overvalued. The stock's GF Value™ is CHF33.48, compared to a current price of CHF39.86 — trading 19.1% above its estimated fair value. The current 3-Year FCF Growth Rate is -29.10%. Fresenius SE KGaA's overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year FCF Growth Rate calculated?
3-Year FCF Growth Rate is calculated from a company's financial statements. For Fresenius SE KGaA (XSWX:FRE), the current 3-Year FCF Growth Rate is -29.10% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fresenius SE KGaA (XSWX:FRE) Overvalued in 2026?
Based on GuruFocus' analysis, Fresenius SE KGaA stock appears to be overvalued.
The current stock price of CHF39.86 is trading 19.1% above its estimated GF Value™ of CHF33.48.
GuruFocus considers Fresenius SE KGaA to be Modestly Overvalued.
Key valuation signals for XSWX:FRE:
3-Year FCF Growth Rate: -29.10%
GF Value™: CHF33.48 vs. price of CHF39.86 (19.1% above fair value)
No single metric tells the full story. See the XSWX:FRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fresenius is a healthcare holding company based in Germany. The company owns a minority stake in dialysis service provider and equipment manufacturer Fresenius Medical Care. The Kabi segment manufactures intravenous drugs, nutrition products, infusion and transfusion therapies, and related pumps. The Helios segment operates private hospitals primarily in Germany and Spain.
67GF Score
Get the complete analysis for XSWX:FRE
3-Year FCF Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:FRE has been successfully added to your 
